Society Roundtable Prioritizes Hypoglycemia

On April 29, the Society co-hosted a roundtable with Merck to discuss the current hypoglycemia landscape and to delve deeper into policy priorities that were identified at our diabetes policy summit last September. The roundtable featured key officials from professional societies, patient advocates, quality improvement organizations, and the federal government, including NIDDK, CDC, and Veteran’s Health Administration. At the meeting, participants discussed various perspectives on hypoglycemia as they relate to the patient experience, research and surveillance, issues in the clinical setting, and quality improvement.

The Society will continue working with Merck and participants at the roundtable on initiatives to increase awareness of hypoglycemia and identify areas for collaboration. Tony McCall, MD, PhD, Endocrine Society Vice President for Clinical Science, was our representative and did a masterful job distilling the issues and providing context for next steps. We will keep members apprised of the follow-up.

You may also like

  • Endocrine Society Advocacy Update – March 2024

    Endocrine Society Advocates to Protect and Increase Funding for the NIH  On March 5, the Endocrine Society will conduct a Researcher Hill Day to advocate for the importance of the National Institutes of Health (NIH). We are asking Congress to complete work on a funding bill for the remainder of fiscal year (FY) 2024, before…

  • Advocacy Update: February 2024

    Federal Funding for SDP, NIH in Jeopardy As the February issue of Endocrine News went to press, the government had only days to fund the Special Diabetes Program (SDP) and the National Institutes of Health (NIH) before funding expired.  It was expected that Congress would pass another short-term funding bill that would fund these programs…

Find more in